酒石酸泰万菌素预混剂在仔猪体内的药代动力学研究

Pharmacokinetics of Tyvalosin Tartrate Premix in Piglets

关键词:  酒石酸泰万菌素预混剂  液相色谱-质谱法  仔猪  药代动力学  抗生素残留

Key words:  tyvalosin tartrate premix  liquid chromatography-mass spectrometry  piglet  pharmacokinetics  antibiotic residue

摘要:

为研究酒石酸泰万菌素预混剂在仔猪体内的药物动力学特征，采用平行试验设计方法，将12头28日龄健康仔猪随机分为两组，每组6头（公猪），第1组口服沈阳伟嘉生物技术有限公司的酒石酸泰万菌素预混剂，第2组口服英国伊科拜克动物保健品有限公司的酒石酸泰万菌素预混剂。两组给药剂量相同均为125mg/kg，所有仔猪给药前禁食12h，给药6h后恢复正常饮食。给药后按照预定的采血点采集血样，用液相色谱-质谱法（LC/MS-MS）测定酒石酸泰万菌素预混剂的血浆浓度，用DAS 2.1.1 软件计算药动学参数。结果显示：口服沈阳伟嘉生物技术有限公司的酒石酸泰万菌素预混剂在仔猪体内主要药动学参数如下：平均最高血药浓度（Cmax）为247.3 ng/ml，平均药时曲线下面积（AUC）为1899.0 ng/ml*h,平均达峰时间（Tmax）为1 h；口服英国伊科拜克动物保健品有限公司的酒石酸泰万菌素预混剂主要药动学参数如下：平均最高血药浓度（Cmax）为159.8 ng/ml，平均药时曲线下面积（AUC）为986.0 ng/ml*h,平均达峰时间（Tmax）为1.5 h；结果表明，沈阳伟嘉生物技术有限公司的酒石酸泰万菌素预混剂平均最高血药浓度（Cmax）是参比制剂的1.55倍，平均药时曲线下面积（AUC）是参比制剂的1.93倍，生物利用度是参比制剂的193%；沈阳伟嘉生物技术有限公司的酒石酸泰万菌素预混剂相比参比制剂（英国伊科拜克动物保健品有限公司）具有给药后仔猪体内分布迅速，血药浓度高，药时曲线下面积（AUC）高，生物利用度高，吸收和代谢速度快，药物残留时间短，休药期短，对减少抗生素残留具有重要意义。

Abstract:

To study the pharmacokinetic characteristics of tyvalosin tartrate premix administrated in piglets, we designed a parallel experiment. Twelve 28-day-old healthy piglets were randomly divided into two groups with 6 boars in each group, all of which were administrated orally with the same dosage of 125mg/kg. The administrated tyvalosin tartrate premix in group one was from Shenyang Weijia Biotechnology Co., Ltd. and the group two was from British ECO-BIOK Animal Health Products Co., Ltd. All piglets fasted for 12 h before administration, and resumed normal diet after 6 h of administration. The blood samples were collected according to the predetermined time points. The concentration of tyvalosin tartrate premix in plasma was determined by liquid chromatography-mass spectrometry (LC/MS-MS) method, and the pharmacokinetic parameters were calculated by DAS 2.1.1 software. The calculated results of the main pharmacokinetic parameters in group one were as follows: the average maximum blood concentration (Cmax) was 247.3 ng/ml; the average area under the drug-time curve (AUC) was 1899.0 ng/ml*h; the average peak time (Tmax) was 1 h. For the group two, the calculated results were as follows: the average maximum blood concentration (Cmax) was 159.8 ng/ml; the average area under the drug-time curve (AUC) was 986.0 ng/ml*h; the average peak time (Tmax) was 1.5 h. The above results showed that the average maximum blood concentration (Cmax) in group one was 1.55 times, the average area under the drug-time curve (AUC) was 1.93 times and the bioavailability was 193% compared to reference preparation (group two). Compared with the reference preparation of ECO-BIOK Animal Health Products Co., Ltd., the tyvalosin tartrate premix of Shenyang Weijia Biotechnology Co., Ltd. has a faster distribution in piglets after administration, higher blood concentration, higher average area under the drug-time curve (AUC), higher bioavailability, faster absorption and metabolism rate, shorter drug residue time and shorter drug break period. We conclude that the tyvalosin tartrate premix is of great significance for reducing antibiotic residues.